Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP104 in Primary Biliary Cholangitis
NCT02193360Phase 2Unknown
- Sponsor
- Fast Forward Pharmaceuticals BV
- Start
- May 2015
- Primary completion
- Aug 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of FFP104 in primary biliary cholangitis (PBC), sponsored by Fast Forward Pharmaceuticals BV. Primary endpoint: Safety and tolerability of FFP104 at 24 weeks. Status: unknown.
02
Drugs
FFP104
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02193360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193360.